In AML, overexpression of EZH2 results in the downregulation of tumor suppressor genes, such as p16INK4a and p53, which promotes leukemia cell proliferation and increases resistance to chemotherapy (Huang et al., 2021). The gene discussed is CDKN2A; the disease is acute myeloid leukemia.